Changes in clinical presentation, management and outcome in 1348 patients with differentiated thyroid carcinoma: Experience in a single institute in Hong Kong, 1960-2000

被引:54
作者
Chow, SM
Law, SCK
Au, SK
Mang, O
Yau, S
Yuen, KT
Lau, WH
机构
[1] Queen Elizabeth Hosp, Dept Clin Oncol, Kowloon, Hong Kong, Peoples R China
[2] Hong Kong Canc Registry, Hong Kong, Hong Kong, Peoples R China
关键词
differentiated thyroid carcinoma; papillary carcinoma; follicular carcinoma; presentation; outcome;
D O I
10.1016/S0936-6555(03)00066-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The clinical features, management and outcome of 1348 patients diagnosed with differentiated thyroid carcinoma in Queen Elizabeth Hospital, Hong Kong, were analysed according to the period of diagnosis: A (before 1980), B (1981-1990) and C (1991-2000). As time advanced, ratio of papillary carcinoma (PTC) to follicular carcinoma (FTC) increased (A: B:C=1.6: 3.1: 7.2). The mean size of the primary tumour decreased (A:B:C=3.5 cm: 2.8 cm: 2.5 cm). with a greater percentage of microcarcinoma of I cm or less (A:B:C=5.1%: 16.1%: 21.7%). At presentation, the incidence of lymph-node metastasis decreased (A:B:C=32.7%: 31.6%: 24.8%) and that of distant metastasis decreased (A:B:C=9%: 6.1%: 5.3%). Bilateral surgical resection was more commonly used (A:B:C=62.8%: 89.1%: 94.8%) than lobectomy (A:B:C=26.3%: 2.8%: 1.8%). Radiation treatment, radioactive iodine (I-131, RAI) and external radiotherapy (EXT), was more commonly used (A:B:C=53.2%: 74.7%: 85.1%). RAI was used in 84.3% (A:B:C=50%: 71.2%: 84.3%) and EXT in 14.5% of patients in the past decade (A:B:C 10.9%: 8.7%: 14.5%). The proportion of patients who adopted a bilateral surgery and RAI treatment increased gradually with time (A:B:C=33%: 68%: 83.8%). The 5-year cause-specific survival (A:B:C=90.2%: 93.7%: 95.7%,), locoregional failure-free survival (A:B:C -72.6%: 82.9%: 91.6%) and distant metastasis failure-free survival (A:B:C=84.5%: 89.1%: 92.6%) were improved. However, the period of diagnosis was not found to be an important explanatory variable (i.e. P>0.05) in Cox regression after adjusting for other factors, indicating that the improvement was probably related to the temporal trend of other factors: presentation at earlier stage. increased ratio of PTC:FTC and more aggressive management by bilateral surgery and radiation therapy.
引用
收藏
页码:329 / 336
页数:8
相关论文
共 64 条
[51]   PULMONARY METASTASIS OF DIFFERENTIATED THYROID-CARCINOMA - TREATMENT RESULTS IN 101 PATIENTS [J].
SAMAAN, NA ;
SCHULTZ, PN ;
HAYNIE, TP ;
ORDONEZ, NG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1985, 60 (02) :376-380
[52]   THE RESULTS OF VARIOUS MODALITIES OF TREATMENT OF WELL DIFFERENTIATED THYROID-CARCINOMA - A RETROSPECTIVE REVIEW OF 1599 PATIENTS [J].
SAMAAN, NA ;
SCHULTZ, PN ;
HICKEY, RC ;
GOEPFERT, H ;
HAYNIE, TP ;
JOHNSTON, DA ;
ORDONEZ, NG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (03) :714-720
[53]  
Schlumberger M, 1996, J NUCL MED, V37, P598
[54]   LOBECTOMY VERSUS TOTAL THYROIDECTOMY FOR DIFFERENTIATED CARCINOMA OF THE THYROID - A MATCHED-PAIR ANALYSIS [J].
SHAH, JP ;
LOREE, TR ;
DHARKER, D ;
STRONG, EW .
AMERICAN JOURNAL OF SURGERY, 1993, 166 (04) :331-335
[55]   PAPILLARY AND FOLLICULAR THYROID-CANCER - IMPACT OF TREATMENT IN 1578 PATIENTS [J].
SIMPSON, WJ ;
PANZARELLA, T ;
CARRUTHERS, JS ;
GOSPODAROWICZ, MK ;
SUTCLIFFE, SB .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1988, 14 (06) :1063-1075
[56]  
Sobin LH, 1997, TNM CLASSIFICATION M
[57]  
Staunton M D, 1994, Eur J Surg Oncol, V20, P613
[58]   Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma [J].
Taylor, T ;
Specker, B ;
Robbins, J ;
Sperling, M ;
Ho, M ;
Ain, K ;
Bigos, ST ;
Brierley, J ;
Cooper, D ;
Haugen, B ;
Hay, I ;
Hertzberg, V ;
Klein, I ;
Klein, H ;
Ladenson, P ;
Nishiyama, R ;
Ross, D ;
Sherman, S ;
Maxon, HR .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (08) :622-+
[59]  
Tsang TW, 1998, CANCER-AM CANCER SOC, V82, P375
[60]  
TUBIANA M, 1985, CANCER, V55, P2062, DOI 10.1002/1097-0142(19850501)55:9+<2062::AID-CNCR2820551406>3.0.CO